1
|
Del Bufalo D, Damia G. Overview of BH3 mimetics in ovarian cancer. Cancer Treat Rev 2024; 129:102771. [PMID: 38875743 DOI: 10.1016/j.ctrv.2024.102771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 05/09/2024] [Accepted: 05/21/2024] [Indexed: 06/16/2024]
Abstract
Ovarian carcinoma is the leading cause of gynecological cancer-related death, still with a dismal five-year prognosis, mainly due to late diagnosis and the emergence of resistance to cytotoxic and targeted agents. Bcl-2 family proteins have a key role in apoptosis and are associated with tumor development/progression and response to therapy in different cancer types, including ovarian carcinoma. In tumors, evasion of apoptosis is a possible mechanism of resistance to therapy. BH3 mimetics are small molecules that occupy the hydrophobic pocket on pro-survival proteins, allowing the induction of apoptosis, and are currently under study as single agents and/or in combination with cytotoxic and targeted agents in solid tumors. Here, we discuss recent advances in targeting anti-apoptotic proteins of the Bcl-2 family for the treatment of ovarian cancer, focusing on BH3 mimetics, and how these approaches could potentially offer an alternative/complementary way to treat patients and overcome or delay resistance to current treatments.
Collapse
Affiliation(s)
- Donatella Del Bufalo
- Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Via E. Chianesi 53, 00144 Rome, Italy.
| | - Giovanna Damia
- Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy.
| |
Collapse
|
2
|
Meryet-Figuière M, Lecerf C, Varin E, Coll JL, Louis MH, Dutoit S, Giffard F, Blanc-Fournier C, Hedir S, Vigneron N, Brotin E, Pelletier L, Josserand V, Denoyelle C, Poulain L. Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route. Oncol Rep 2017; 38:1949-1958. [PMID: 28791387 PMCID: PMC5652939 DOI: 10.3892/or.2017.5882] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 06/12/2017] [Indexed: 12/16/2022] Open
Abstract
Ovarian cancer is the leading cause of death from gynecological malignancies worldwide, and innate or acquired chemoresistance of ovarian cancer cells is the major cause of therapeutic failure. It has been demonstrated that the concomitant inhibition of Bcl-xL and Mcl-1 anti-apoptotic activities is able to trigger apoptosis in chemoresistant ovarian cancer cells. In this context, siRNA-mediated Bcl‑xL and Mcl-1 inhibition constitutes an appealing strategy by which to eliminate chemoresistant cancer cells. However, the safest and most efficient way to vectorize siRNAs in vivo is still under debate. In the present study, using in vivo bioluminescence imaging, we evaluated the interest of atelocollagen to vectorize siRNAs by intraperitoneal (i.p.) or intravenous (i.v.) administration in 2 xenografted ovarian cancer models (peritoneal carcinomatosis and subcutaneous tumors in nude mice). Whereas i.p. administration of atelocollagen-vectorized siRNA in the peritoneal carcinomatosis model did not induce any gene downregulation, a 70% transient downregulation of luciferase expression was achieved after i.v. injection of atelocollagen-vectorized siRNA in the subcutaneous (s.c.) model. However, the use of siRNA targeting Bcl-xL or Mcl-1 did not induce target-specific downregulation in vivo in nude mice. Our results therefore show that atelocollagen complex formulation, the administration route, tumor site and the identity of the siRNA target influence the efficiency of atelocollagen‑mediated siRNA delivery.
Collapse
Affiliation(s)
- Matthieu Meryet-Figuière
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Charlotte Lecerf
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Emilie Varin
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Jean-Luc Coll
- INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France
| | - Marie-Hélène Louis
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Soizic Dutoit
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Florence Giffard
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Cécile Blanc-Fournier
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Siham Hedir
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Nicolas Vigneron
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Emilie Brotin
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Laurent Pelletier
- INSERM U836, Grenoble Institute of Neurosciences, Bâtiment Edmond J. Safra, Chemin Fortuné Ferrini, Site Santé, 38706 La Tronche Cedex, France
| | - Véronique Josserand
- INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France
| | - Christophe Denoyelle
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| | - Laurent Poulain
- INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France
| |
Collapse
|
3
|
Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death. J Ovarian Res 2015; 8:36. [PMID: 26063499 PMCID: PMC4470044 DOI: 10.1186/s13048-015-0165-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 06/02/2015] [Indexed: 01/09/2023] Open
Abstract
Background Ovarian carcinoma is the leading cause of death from gynecological cancer because there is risk of chemoresistance. As previously demonstrated in our laboratory, Alpha-lipoic acid (LA), a co-factor for metabolic enzymes, suppresses the tumor growth. In this study, we have researched the mechanisms that are responsible for the activity of LA. Methods We have studied the mechanisms of LA in two ovarian cancer cell lines, a cisplatin sensitive one, IGROV1 and its resistant counterpart, IGROV1-R10. These cells have been exposed to lipoic acid at various concentrations. Cell proliferation, cell cycle repartition and nuclear staining with DAPI were recorded. Western blot analyses were performed to detect various proteins implied in apoptotic cell death pathways. To investigate the formation of ROS, the oxidation of CM-DCFH2-DA were also determined. Findings LA suppressed growth proliferation and induced apoptosis in both ovarian cell lines. Moreover, LA provoked a down regulation of two anti-apoptotic proteins, Mcl-1 and Bcl-xL protein and a strong induction of the BH3-only protein Bim. Furthermore, LA induced ROS generation which could be involved in the CHOP induction which is known to activate the Bim translation. Conclusions Our results reveal novel actions of LA which could explain the anti-tumoral effects of the LA. Therefore, LA seems to be a promising compound for ovarian cancer treatment.
Collapse
|
4
|
Tomasina J, Poulain L, Abeilard E, Giffard F, Brotin E, Carduner L, Carreiras F, Gauduchon P, Rault S, Malzert-Fréon A. Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma. Int J Pharm 2013; 458:197-207. [PMID: 24084450 DOI: 10.1016/j.ijpharm.2013.09.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Revised: 09/20/2013] [Accepted: 09/22/2013] [Indexed: 01/22/2023]
Abstract
We report the development of folate-functionalized nanoparticles able to target folate receptors, and to deliver a poorly water soluble cytotoxic agent, a tripentone, in ovarian carcinoma. The stability under incubation of lipid nanoparticles formulated by a low-energy phase inversion temperature method was investigated. Thanks to the presence of Labrasol(®), a macrogolglyceride into the composition of the nanocarriers, the conjugation of different quantities of a folate derivate (folic acid-polyethylene glycol2000-distearylphosphatidylethanolamine) to nanoparticles was possible by a rapid, soft, very simple post-insertion process. As determined by dynamic light scattering, nanoparticles present a monodisperse diameter of about 100 nm, a spherical shape as attested by transmission electron micrographs, a weakly negative surface zeta potential, and are able to encapsulate the tripentone MR22388. The presence of folate receptors on SKOV3 human ovarian cancer cells was identified by fluorescent immunocytochemistry. Cellular uptake studies assessed by flow cytometry indicated that these nanoparticles reached the SKOV3 cells rapidly, and were internalized by a folate-receptor mediated endocytosis pathway. Moreover, nanoparticles allowed the rapid delivery of the antitumor agent tripentone into cells as shown in vitro by real-time cellular activity assay. Such folate-lipid nanoparticles are a potential carrier for targeted delivery of poorly water soluble compounds into ovarian carcinoma.
Collapse
Affiliation(s)
- J Tomasina
- Normandie Univ, France; UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie - FR CNRS INC3M - SF ICORE, Université de Caen Basse-Normandie, UFR des Sciences Pharmaceutiques Bd Becquerel), F-14032 Caen, France; UNICAEN, BioTICLA (Centre de Lutte Contre le Cancer F Baclesse, SF ICORE, Université de Caen Basse-Normandie, UFR des Sciences Pharmaceutiques Bd Becquerel), F-14032 Caen, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|